Inside the unconventional FDA panel that could reshape the peptide industry

Peptides are under scrutiny in an FDA meeting running July 23-24 Olena Malik/Getty Images An unconventional FDA panel is reviewing peptide safety, focusing on banned therapeutic peptides. The FDA raised concerns over peptide safety, citing immune reactions and a lack of evidence of efficacy. Better access to peptides could open up a multibillion-dollar market for telehealth companies. Nearly 2 years after Robert F. Kennedy Jr. vowed to end the FDA's "war" on peptides, he has convened an unusual FDA advisory committee. A panel is meeting this week to weigh the future of several popular peptides — including trendy compounds prized for injury recovery, fat loss, and sleep that the FDA has banned. Unlike a typical FDA panel, several members make their living prescribing, researching, or selling peptide therapies, raising questions about how the debate will unfold. The compounds under review aren't GLP-1 drugs or insulin — both FDA-approved peptides.